Our top pick for
24/5 trading
AbbVie Inc (ABBV) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$171.52. During the previous open market day, the price has varied from a low of USD170.3411 to a high of USD173.88. AbbVie is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in AbbVie
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for AbbVie. Find the share by name or ticker symbol: ABBV. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AbbVie reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$171.52, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of AbbVie, depending on your broker.
- Check in on your investment. Congratulations, you own a part of AbbVie. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
AbbVie shares at a glance
Information last updated 2024-12-19.
| 52-week range | US$147.6814 - US$207.32 |
|---|---|
| 50-day moving average | US$184.001 |
| 200-day moving average | US$178.9361 |
| Target price | US$202.5421 |
| PE ratio | 60.2857 |
| Dividend yield | US$6.2 (3.79%) |
| Earnings per share (TTM) | US$2.87 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
AbbVie price performance over time
Historical closes compared with the last close of $171.52
| 1 week (2024-12-13) | -1.07% |
|---|---|
| 1 month (2024-11-20) | 2.24% |
| 3 months (2024-09-20) | -11.35% |
| 6 months (2024-06-20) | -0.35% |
| 1 year (2023-12-20) | 13.07% |
|---|---|
| 2 years (2022-12-20) | 6.81% |
| 3 years (2021-12-20) | 31.07% |
| 5 years (2019-12-20) | 92.09% |
Compare trading platforms to buy AbbVie shares
1 - 5 of 26
Compare alternatives
We currently don't have a partnership for that product, but we have other similar offers to choose from (how we picked these ):
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is AbbVie under- or over-valued?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, AbbVie shares trade at around 60x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4133. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$25.6 billion (£20.2 billion).
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure stock profitability.
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as US$147.6814 up to US$207.32. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.613. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie financials
| Revenue TTM | US$55.5 billion |
|---|---|
| Operating margin TTM | 28.93% |
| Gross profit TTM | US$41.5 billion |
| Return on assets TTM | 7.72% |
| Return on equity TTM | 56.41% |
| Profit margin | 9.22% |
| Book value | 3.413 |
| Market capitalisation | US$305.8 billion |
| EBITDA | US$25.6 billion |
TTM: trailing 12 months
AbbVie share dividends
Dividend payout ratio: 58.51% of net profits
Recently AbbVie has paid out, on average, around 58.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.79% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.79% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.2 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 13 February 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 January 2025 (the "ex-dividend date").
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
AbbVie Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 34.86 |
|---|---|
| Total ESG percentile | 65.78 |
| Environmental score | 4.96 |
| Environmental score percentile | 7 |
| Social score | 22.65 |
| Social score percentile | 7 |
| Governance score | 16.25 |
| Governance score percentile | 7 |
| Level of controversy | 3 |
AbbVie overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie in the news
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
AbbVie Stock Slides on Schizophrenia Drug Study Failure
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Frequently asked questions
More resources on Finder
More guides on Finder
-
The best options trading platforms in Australia 2024
We've compared the fees and features of 40 trading platforms to find the best picks for options traders in Australia.
-
Webull Australia review
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
-
The best day trading platforms in Australia
The best day trading platforms in Australia offer low fees and are packed full of features essential for algorithmic trading.
-
Best stocks under $5 in Australia (2024)
We used Finder's proprietary algorithm to find Australian-listed companies that have strong fundamentals and have a share price under $5.
-
The best ASX penny stocks (updated weekly)
Big gainers included NoviqTech, Octava Minerals and Singular Health Group.
-
Best performing stocks on the ASX (Updated weekly)
Top gainers included SSR Mining Inc, Appen and Insignia Financial.
-
Tiger Brokers Australia review
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
-
The cheapest stock brokers in Australia December 2024
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
-
Options Trading in Australia 2024
A beginner's guide to options trading in Australia. Read the step-by-step process and compare brokers to start trading.
-
The best share trading platforms in Australia
Follow these tips to find the best share trading platform for you.
Ask a question